RIDGEVIEW INSTITUTE SMYRNA — History
CCN 114012 | 3-year financial timeline | COVID resilience: 57/100
🛡️ Public data only — no PHI permitted on this instance.
$40M
Latest Revenue (FY2022)
+5.6%
Revenue CAGR (3yr)
20.8%
Financial Timeline
| Metric | FY2020 | FY2021 | FY2022 | YoY (Latest) | CAGR |
|---|---|---|---|---|---|
| Net Patient Revenue | $36M | $39M | $40M | +3.2% | +5.6% |
| Operating Expenses | $28M | $31M | $32M | +2.3% | +5.7% |
| Operating Margin | 20.9% | 20.0% | 20.8% | +3.6% | -0.4% |
| Net Income | $8M | $8M | $8M | +7.0% | +5.2% |
| Licensed Beds | 188 | 188 | 188 | +0.0% | +0.0% |
| Total Patient Days | 39,816 | 42,505 | 44,829 | +5.5% | +6.1% |
| Medicare Day % | 14% | 13% | 11% | -11.5% | -11.4% |
| Medicaid Day % | 0% | 0% | 0% | +413.6% | +72.8% |
COVID Impact & Recovery
Resilience Score: 57/100 — Moderate — some COVID impact but recovering
Revenue recovery from FY2020 to FY2022: +11.6% ($36M → $40M)
FY2020 captured the initial COVID shock. Strong recovery indicates operational resilience and payer diversification.
Trend Summary
Revenue▲ Growing
Operating Margin▶ Stable
Beds▶ Stable
Medicare Mix▲ Growing
vs State Average ()
Revenue Growth
+5.6%
This Hospital
+7.6%
State Avg
Latest Margin
20.8%
This Hospital
-4.6%
State Avg
Projections (FY2023-2025)
Extrapolated from 3-year trend using linear projection. Does not account for regulatory or market changes.
| Year | Revenue (proj) | Margin (proj) |
|---|---|---|
| FY2023 (proj) | $42M | 20.7% |
| FY2024 (proj) | $44M | 20.6% |
| FY2025 (proj) | $46M | 20.5% |